These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 9236955)

  • 1. Multicenter evaluation of new instruments for Alzheimer's disease clinical trials: summary of results. The Alzheimer's Disease Cooperative Study.
    Mackell JA; Ferris SH; Mohs R; Schneider L; Galasko D; Whitehouse P; Schmitt F; Sano M; Thal LJ
    Alzheimer Dis Assoc Disord; 1997; 11 Suppl 2():S65-9. PubMed ID: 9236955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A multicenter evaluation of new treatment efficacy instruments for Alzheimer's disease clinical trials: overview and general results. The Alzheimer's Disease Cooperative Study.
    Ferris SH; Mackell JA; Mohs R; Schneider LS; Galasko D; Whitehouse PJ; Schmitt FA; Sano M; Thomas RG; Ernesto C; Grundman M; Schafer K; Thal LJ
    Alzheimer Dis Assoc Disord; 1997; 11 Suppl 2():S1-12. PubMed ID: 9236947
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Spanish Instrument Protocol: design and implementation of a study to evaluate treatment efficacy Instruments for Spanish-speaking patients with Alzheimer's disease. The Alzheimer's Disease Cooperative Study.
    Sano M; Mackell JA; Ponton M; Ferreira P; Wilson J; Pawluczyk S; Pfeiffer E; Thomas RG; Jin S; Schafer K; Schittini M; Grundman M; Ferris SH; Thal LJ
    Alzheimer Dis Assoc Disord; 1997; 11 Suppl 2():S57-64. PubMed ID: 9236954
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ADCS Prevention Instrument Project: overview and initial results.
    Ferris SH; Aisen PS; Cummings J; Galasko D; Salmon DP; Schneider L; Sano M; Whitehouse PJ; Edland S; Thal LJ;
    Alzheimer Dis Assoc Disord; 2006; 20(4 Suppl 3):S109-23. PubMed ID: 17135805
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer's Disease Assessment Scale that broaden its scope. The Alzheimer's Disease Cooperative Study.
    Mohs RC; Knopman D; Petersen RC; Ferris SH; Ernesto C; Grundman M; Sano M; Bieliauskas L; Geldmacher D; Clark C; Thal LJ
    Alzheimer Dis Assoc Disord; 1997; 11 Suppl 2():S13-21. PubMed ID: 9236948
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The severe impairment battery: concurrent validity and the assessment of longitudinal change in Alzheimer's disease. The Alzheimer's Disease Cooperative Study.
    Schmitt FA; Ashford W; Ernesto C; Saxton J; Schneider LS; Clark CM; Ferris SH; Mackell JA; Schafer K; Thal LJ
    Alzheimer Dis Assoc Disord; 1997; 11 Suppl 2():S51-6. PubMed ID: 9236953
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study.
    Schneider LS; Olin JT; Doody RS; Clark CM; Morris JC; Reisberg B; Schmitt FA; Grundman M; Thomas RG; Ferris SH
    Alzheimer Dis Assoc Disord; 1997; 11 Suppl 2():S22-32. PubMed ID: 9236949
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study.
    Galasko D; Bennett D; Sano M; Ernesto C; Thomas R; Grundman M; Ferris S
    Alzheimer Dis Assoc Disord; 1997; 11 Suppl 2():S33-9. PubMed ID: 9236950
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A longitudinal study of behavioral pathology across five levels of dementia severity in Alzheimer's disease: the CERAD Behavior Rating Scale for Dementia. The Alzheimer's Disease Cooperative Study.
    Patterson MB; Mack JL; Mackell JA; Thomas R; Tariot P; Weiner M; Whitehouse PJ
    Alzheimer Dis Assoc Disord; 1997; 11 Suppl 2():S40-4. PubMed ID: 9236951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Independence of changes in behavior from cognition and function in community-dwelling persons with Alzheimer's disease: a factor analytic approach.
    Tractenberg RE; Weiner MF; Cummings JL; Patterson MB; Thal LJ
    J Neuropsychiatry Clin Neurosci; 2005; 17(1):51-60. PubMed ID: 15746483
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical utility of the functional independence measure for assessment of patients with Alzheimer's disease and vascular dementia.
    Tanaka N; Nakatsuka M; Ishii H; Nakayama R; Hosaka R; Meguro K
    Psychogeriatrics; 2013 Dec; 13(4):199-205. PubMed ID: 24289460
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cognitive and functional decline and their relationship in patients with mild Alzheimer's dementia.
    Liu-Seifert H; Siemers E; Sundell K; Price K; Han B; Selzler K; Aisen P; Cummings J; Raskin J; Mohs R
    J Alzheimers Dis; 2015; 43(3):949-55. PubMed ID: 25125457
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The sensitivity to change over time of the Bristol Activities of Daily Living Scale in Alzheimer's disease.
    Byrne LM; Wilson PM; Bucks RS; Hughes AO; Wilcock GK
    Int J Geriatr Psychiatry; 2000 Jul; 15(7):656-61. PubMed ID: 10918348
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emergent psychopathology in Alzheimer's disease patients over 12 months associated with functional, not cognitive, changes.
    Tractenberg RE; Weiner MF; Patterson MB; Gamst A; Thal LJ
    J Geriatr Psychiatry Neurol; 2002; 15(2):110-7. PubMed ID: 12083593
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progression of Alzheimer's disease during a three-year follow-up using the CERAD-NB total score: Kuopio ALSOVA study.
    Hallikainen I; Hänninen T; Fraunberg M; Hongisto K; Välimäki T; Hiltunen A; Karppi P; Sivenius J; Soininen H; Koivisto AM;
    Int Psychogeriatr; 2013 Aug; 25(8):1335-44. PubMed ID: 23676340
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Two dimensions of anosognosia in patients with Alzheimer's disease: reliability and validity of the Japanese version of the Anosognosia Questionnaire for Dementia (AQ-D).
    Sato J; Nakaaki S; Murata Y; Shinagawa Y; Matsui T; Hongo J; Tatsumi H; Akechi T; Furukawa TA
    Psychiatry Clin Neurosci; 2007 Dec; 61(6):672-7. PubMed ID: 18081630
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical evaluation of global change in Alzheimer's disease: identifying consensus.
    Olin JT; Schneider LS; Doody RS; Clark CM; Ferris SH; Morris JC; Reisberg B; Schmitt FA
    J Geriatr Psychiatry Neurol; 1996 Oct; 9(4):176-80. PubMed ID: 8970010
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ADCS Prevention Instrument Project: the Mail-In Cognitive Function Screening Instrument (MCFSI).
    Walsh SP; Raman R; Jones KB; Aisen PS;
    Alzheimer Dis Assoc Disord; 2006; 20(4 Suppl 3):S170-8. PubMed ID: 17135810
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Memantine effects measured with the Relevant Outcome Scale for Alzheimer's disease in an open-label, single-arm, multicenter clinical study.
    Holthoff V; Ferris S; Gauthier S; Ihl R; Robert P; Winblad B; Sternberg K; Tennigkeit F;
    Int J Geriatr Psychiatry; 2013 Feb; 28(2):164-72. PubMed ID: 22492589
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ADCS Prevention Instrument Project: ADCS-clinicians' global impression of change scales (ADCS-CGIC), self-rated and study partner-rated versions.
    Schneider LS; Clark CM; Doody R; Ferris SH; Morris JC; Raman R; Reisberg B; Schmitt FA
    Alzheimer Dis Assoc Disord; 2006; 20(4 Suppl 3):S124-38. PubMed ID: 17135806
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.